Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-national phase 2 study to assess the efficacy and safety in patients with solid tumor with NTRK fusions

Next Previous
Trial Profile

A multi-national phase 2 study to assess the efficacy and safety in patients with solid tumor with NTRK fusions

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUM 601 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use

Most Recent Events

  • 20 Oct 2022 According to an AUM Biosciences media release, the company has collaborated with Asymchem to develop and commercially produce AUM 601. The partnership resulted in 10 kg GMP bulk drug substance of AUM 601, which will be used to supply phase 2 trials.
  • 21 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top